Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

inary data and trends may not be predictive of future data or results; the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies; risks related to the conduct of Sunesis' clinical trials and manufacturing; the risk that Sunesis may not be able to monetize its fragment-based drug discovery capabilities and/or intellectual property portfolio; the risk that Sunesis' restructuring costs may be greater than anticipated; the risk that Sunesis' workforce reduction and any future workforce and expense reductions may have an adverse impact on Sunesis' internal programs, Sunesis' ability to hire and retain key personnel and may be distracting to management; and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2007, Sunesis' Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... ALBANY, N.Y. , Oct. 20, 2014 ... pharmaceutical outsourcing facility in Albany, NY ... and trials. The company meets and/or exceeds the FDA ... 210 and 21 CFR Part 211. ... provide the highest levels of quality assurance and quality ...
(Date:10/19/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Wednesday, October 29, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Wednesday, October 29 1:30 ...
(Date:10/17/2014)... 17, 2014  Training market researchers to spot ... factor in today,s highly competitive global marketplace. As ... that effectively and efficiently produce high performing analysts, ... Effective training programs can help ... from internal clients by developing analysts who can ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... , MINNETONKA, Minn., Dec. 1 ... company specializing in clinical study management systems, today ... technology solution, has been certified by the Clinical ... the Operational Data Model (ODM) standard. This ...
... , CAMBRIDGE, Mass. and TOKYO, Dec. 1 Galenea ... further extension of their research and development collaboration through ... to seven years and brings the total committed funding ... working together since January 2005 with the goal of ...
Cached Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel Film ... FCPX filmmakers . , “Fun, cool, and simple are ... Says Christina Austin, CEO of Pixel Film Studios. “It has ... comes with all the tools needed for a full ... added style, a title screen for an introduction, two lower ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... the 12 Million Americans With Food Allergy, FAIRFAX, ... (FAAN) will sponsor an educational briefing on Capitol,Hill to ... honor of,the 11th annual Food Allergy Awareness Week, May ... the challenges of food allergy,through five steps aimed at ...
... Va., May 8 Pending cuts to the,Medicare ... of,physical therapists to serve the rehabilitation needs of ... costs while decreasing quality of,care, according to the ... Section., In testimony May 8 before a ...
... gruesome,discovery of aborted babies in a dumpster behind Dr. ... a Pro-Life Society,discovered the mutilated bodies of aborted babies ... owned by Dr. Reginald Sharpe., "It is indeed ... that we,must stop and take time to grieve the ...
... Tenn., May 8 TeamHealth Inc.,s parent,company, Team ... the,first quarter ended March 31, 2008., The ... anesthesia,management services business line and substantially completed the ... of 2007. As a result, in,accordance with relevant ...
... Care Conference on May 13 - ... on May 14 -, SAN DIEGO, May 8 Gen-Probe Incorporated,(Nasdaq: ... Bank of,America 2008 Health Care Conference in Las Vegas on May 13, ... the Baird,Growth Stock Conference in Chicago on May 14, 2008 at approximately ...
... increased odds of heart attack, death, study finds , , THURSDAY, ... doctor can hear when passing a stethoscope over a main ... heart attack and death from heart disease and stroke, a ... bruit (pronounced brew-ee) -- is caused by turbulent blood flow ...
Cached Medicine News:Health News:Five Steps Forward for Food Allergy 2Health News:Medicare Fee Cuts Could Devastate Rehabilitation Services, Physical Therapists Warn Congress 2Health News:Medicare Fee Cuts Could Devastate Rehabilitation Services, Physical Therapists Warn Congress 3Health News:Medicare Fee Cuts Could Devastate Rehabilitation Services, Physical Therapists Warn Congress 4Health News:ALL: More Dead Babies Found in Michigan Dumpsters 2Health News:Team Finance LLC Announces First Quarter 2008 Results 2Health News:Team Finance LLC Announces First Quarter 2008 Results 3Health News:Team Finance LLC Announces First Quarter 2008 Results 4Health News:Team Finance LLC Announces First Quarter 2008 Results 5Health News:Team Finance LLC Announces First Quarter 2008 Results 6Health News:Team Finance LLC Announces First Quarter 2008 Results 7Health News:Gen-Probe to Webcast Two Upcoming Investor Presentations 2Health News:Noise in Artery Could Warn of Heart Risk 2
... Re-insulation capabilities that extend the life ... that bring them back to life, expertise ... Instrument trademark. Our maintenance capabilities always help ... , Economical and fast, not only do ...
Inquire...
... your camera upon arrival.,Our technician then makes note ... with a thorough customer quote. We respect that ... so well help you prioritize repairs. With customer ... , ISI uses only OEM or widely approved ...
... an ISI technician carefully inspects your ... and all problems, and provides you ... respect that you may be working ... help you prioritize repairs. With customer ...
Medicine Products: